Why typhoid is becoming harder to treat in India

Doctors and public health researchers have raised alarm over typhoid becoming progressively harder to treat in India, driven by the misuse of antibiotics, po...

What Happened

Doctors and public health researchers have raised alarm over typhoid becoming progressively harder to treat in India, driven by the misuse of antibiotics, poor sanitation infrastructure, and gaps in clinical diagnosis.
Extensively Drug-Resistant (XDR) typhoid — a strain that does not respond to five classes of antibiotics — has been identified in India, with researchers sequencing 3,489 S. Typhi strains documenting its spread across South Asia.
India carries an estimated 4.8–4.9 million typhoid cases annually, making it one of the highest-burden countries globally; the disease causes approximately 7,850 deaths per year.
Only one oral antibiotic — azithromycin — currently remains effective for most typhoid strains, with resistance-conferring mutations now threatening even this last oral option; intravenous carbapenems are the remaining alternative.
Experts stress vaccination through the Typhoid Conjugate Vaccine (TCV) and strengthening sanitation as the primary defence, as treatment options continue to narrow.

Static Topic Bridges

Antimicrobial Resistance (AMR) — Causes and Global Context

Antimicrobial Resistance occurs when microorganisms — bacteria, viruses, fungi, or parasites — evolve mechanisms to defeat drugs designed to kill them, rendering standard treatments ineffective. The WHO identifies AMR as one of the ten greatest global public health threats. In typhoid, resistance has evolved progressively: from multidrug resistance (MDR) to XDR (extensively drug-resistant) strains that withstand fluoroquinolones, third-generation cephalosporins, ampicillin, chloramphenicol, and trimethoprim/sulfamethoxazole simultaneously.

The primary drivers of AMR in India include over-the-counter antibiotic sales without prescription, incomplete antibiotic courses, agricultural use of antibiotics, and inadequate sewage treatment that allows resistant bacteria to contaminate water sources.
XDR typhoid was first reported on a large scale in Pakistan in 2016–2018; transmission to India and other South Asian countries followed through genomic spread identified in nearly 200 international spread events since 1990.
India's National Action Plan on Antimicrobial Resistance (NAP-AMR), launched in 2017, provides the policy framework, but implementation gaps in diagnostics and antibiotic stewardship persist.
If untreated, up to 20% of typhoid cases can be fatal.

Connection to this news: The narrowing of effective oral antibiotics to a single drug (azithromycin) represents the most advanced stage of AMR progression in typhoid and underscores the urgency of both vaccine-led prevention and strict antibiotic stewardship in India.

Typhoid Conjugate Vaccine (TCV) and India's Universal Immunisation Programme

The Typhoid Conjugate Vaccine is a new-generation vaccine that conjugates (links) the typhoid Vi polysaccharide antigen to a carrier protein, producing a stronger, longer-lasting immune response. Unlike the older Vi polysaccharide vaccine (ViPS), TCV is effective from six months of age and provides durable protection, making it suitable for inclusion in childhood immunisation schedules.

India's National Technical Advisory Group on Immunisation (NTAGI) recommended TCV inclusion in the Universal Immunisation Programme (UIP) in 2022, primarily alongside the measles-containing vaccine at 9–12 months of age.
The WHO has prequalified four TCV formulations as of April 2025, enabling Gavi-supported procurement for low- and middle-income countries.
India's most recent typhoid treatment guidelines (July 2025) exclude fluoroquinolones entirely, recommending third-generation cephalosporins and azithromycin as primary drugs.
The Universal Immunisation Programme currently covers 12 vaccine-preventable diseases across all states.

Connection to this news: NTAGI's 2022 TCV recommendation, if rapidly scaled under the UIP, could dramatically reduce typhoid incidence and slow the emergence of further resistance by reducing the number of infections requiring antibiotic treatment.

Sanitation, WASH, and the Link to Waterborne Diseases

Typhoid fever (caused by Salmonella Typhi) is a waterborne and food-borne disease, transmitted through consumption of water or food contaminated with human faeces. Its persistence in India is therefore fundamentally linked to gaps in Water, Sanitation, and Hygiene (WASH) infrastructure.

The Jal Jeevan Mission (JJM) aims to provide tap water connections to all rural households by 2024; access to safe piped water is the single most important structural intervention for typhoid elimination.
The Swachh Bharat Mission (SBM) addressed open defecation, but safe sewage treatment and faecal sludge management remain incomplete in urban areas, continuing to contaminate water sources.
Diagnostic gaps — reliance on the Widal test (which has poor sensitivity/specificity) rather than blood cultures — lead to empirical antibiotic prescription without identifying the strain, accelerating resistance.

Connection to this news: Experts specifically cite poor sanitation and diagnostic gaps alongside antibiotic misuse as co-equal drivers of typhoid's drug-resistance crisis, making this a multi-sectoral governance challenge, not purely a medical one.

Key Facts & Data

Annual typhoid cases in India: ~4.8–4.9 million; deaths: ~7,850 per year
XDR typhoid resists: ampicillin, chloramphenicol, trimethoprim/sulfamethoxazole, fluoroquinolones, and third-generation cephalosporins
Last effective oral antibiotic: azithromycin; IV option: carbapenems
NTAGI recommended TCV for UIP: 2022
India's NAP-AMR launched: 2017
WHO prequalified TCV formulations: 4 (as of April 2025)
Fatality rate if untreated: up to 20%
Causative organism: Salmonella Typhi (bacterium)